Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pricing Debate

Set Alert for Pricing Debate

BIO Notebook: Dealing With Rejection, Worrying About March-In Rights, And More

Insights from the first day of the international convention in San Diego also includes interviews on Alzheimer’s investments, dealmaking for mid-sized companies and reflections on the virtues of lean thinking.

BIO Deals

The Looming US Election Weighs On The Minds Of Pharma

The US presidential election in November could mean IRA expansion from a Biden win, but a Trump victory also brings uncertainty.

Politics Policy

Hypertension To Mental Health Drugs: Indian Firms Supplied Bulk Of Rx Volume In US

Indian firms accounted for over 50% of prescription volumes in five of the top 10 therapy areas in the US in 2022, as also 15% of the volume share of biosimilars, delivering savings and widening patient coverage a study by IQVIA said, while also highlighting supply chain risks that need attention.

Commercial Generic Drugs

Obesity Gold Rush To Drive Significant Spending Growth Through Decade, IQVIA Says

IQVIA’s latest usage and spending trends report forecasts US obesity market will grow to $35bn by 2028, while the two leading GLP-1 agonists have already posted eye-popping sales growth.

Pricing Debate Metabolic Disorders

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.

Biosimilars Commercial

AstraZeneca Joins The $35 Club With Cap On Inhaler Copays

The British drug maker’s move follows that of Boehringer Ingelheim earlier this month, which itself followed increasing political scrutiny on out-of-pocket costs.

Pricing Debate Pricing Strategies

Stock Watch: Advanced Therapies Deliver Fourth-Quarter Flop

As drug pricing continues its ascent among hot button issues, the multi-million-dollar price tags for one-and-done advanced therapies, their justification and reimbursement all remain unaligned.

Pricing Debate Gene Therapy

BIO Chair Ted Love On Drug Pricing And Political Pressure

Biopharma veteran Ted Love assured industry that the sector remains fundamentally strong during remarks at the BIO CEO & Investor Conference.

Leadership Pricing Debate

Sanofi Chief Issues Warning To Innovation-Unfriendly EU

Paul Hudson told Scrip that while the EU's prioritization on matters such as boosting hydrogen use and electric car batteries was laudable, delivery of healthcare and the innovation associated with it should be "a strategic imperative."

Innovation Europe

ICER Suggests Big Price Cut For Novartis’s New PNH Drug

The pricing watchdog said 94% of Fabhalta’s price comes from offsetting the cost of AstraZeneca’s Ultomiris, while Novartis said ICER’s analysis has “substantial challenges.”

Pricing Debate Blood & Coagulation Disorders

Paying For Obesity Drugs: The Looming Affordability Crisis

As use of new obesity medicines become more widespread, experts at the J.P. Morgan Healthcare conference predicted that paying for them will stress state governments and employers.

Market Access Reimbursement

What’s Next For ICER: An Interview With New President Sarah Emond

The Institute for Clinical and Economic Review’s new president talked to Scrip in an interview about cell and gene therapy, obesity drugs and the new Medicare drug price negotiation program.

Pricing Debate Gene Therapy

The ‘Haves And Have-Nots’ Are Becoming Clearer In Cell And Gene Therapy

2023 saw a number of gene therapy companies go to the wall, but those that can combine clinical significance and commercial success can build sustainable businesses.

Gene Therapy Regenerative Medicine

J.P. Morgan 2024: Optimism With An Undercurrent Of Tension

An uptick in deals and an improving macro-economic outlook laid the groundwork for a rosier sentiment across much of the industry at the annual health care conference.

Business Strategies Gene Therapy

Costs From ICER’s Unsupported Price Increase List Tick Back Up

Humira topped ICER’s list of drugs with unsupported price increases that added the most cost to the US health care system during 2022, its last year before biosimilars hit the US market.

Cost Effectiveness Pricing Debate

Biden's Latest Rx Pricing Moves Are At Once Bold And Incremental

As the president’s reelection campaign themes take shape, the administration is preparing to leverage NIH patents in ways it had previously eschewed. As with the merger oversight effort, though, the germs of the plans began earlier in Biden’s tenure.

Pricing Debate Intellectual Property
See All
UsernamePublicRestriction

Register